Oxford Asset Management’s AnaptysBio ANAB Stock Holding History

Oxford Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,676	Closed	-$703K	–	383
2026 Q1	$703K	Buy	+12,676	New	+$682K	0.28%	103
2025 Q2	–	Sell	-14,473	Closed	-$269K	–	527
2025 Q1	$269K	Buy	+14,473	New	+$241K	0.12%	283
2019 Q4	–	Sell	-28,563	Closed	-$999K	–	1734
2019 Q3	$999K	Buy	28,563 +17,212	+152%	+$819K	0.02%	943
2019 Q2	$640K	Buy	11,351 +3,823	+51%	+$275K	0.01%	1167
2019 Q1	$550K	Buy	+7,528	New	+$520K	0.01%	1177
2018 Q1	–	Sell	-10,031	Closed	-$1.01M	–	1586
2017 Q4	$1.01M	Buy	+10,031	New	+$738K	0.02%	928

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Oxford Asset Management's ANAB Position: Q2 2026 in Review

Oxford Asset Management sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 12,676 shares — an estimated $703K sold.

Oxford Asset Management first reported a position in ANAB in Q4 2017 and held it in 6 quarters. The position peaked at $1.01M in Q4 2017. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Oxford Asset Management reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
Oxford Asset Management sold 12,676 AnaptysBio shares in Q2 2026, an estimated $703K.
Oxford Asset Management first reported a position in AnaptysBio in Q4 2017 and held it in 6 quarters.
Oxford Asset Management's AnaptysBio position peaked at $1.01M in Q4 2017.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.